Neoadjuvant and Adjuvant Chemotherapy Treatment Patterns Among Older Triple-negative and HER2-positive Breast Cancer Patients with Comorbidities

被引：0
|
作者：
Tamirisa, Nina [1 ]
Dong, Wenli [1 ]
Shen, Yu [1 ]
Shaitelman, Simona [1 ]
Babiera, Gildy [1 ]
Bedrosian, Isabelle [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1387856
引用
收藏
页码：S315 / S316
页数：2
相关论文
共 50 条
  • [21] Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer
    Ochi, Tomohiro
    Tsunoda, Hiroko
    Matsuda, Naoko
    Nozaki, Fumi
    Suzuki, Koyu
    Takei, Hiroyuki
    Yamauchi, Hideko
    BREAST CANCER, 2021, 28 (04) : 838 - 847
  • [22] Impact of Location of Residence and Distance to Cancer Centre on Medical Oncology Consultation and Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
    Yee, Elliott K.
    Hallet, Julie
    Hong, Nicole J. Look
    Nguyen, Lena
    Coburn, Natalie
    Wright, Frances C.
    Gandhi, Sonal
    Jerzak, Katarzyna J.
    Eisen, Andrea
    Roberts, Amanda
    CURRENT ONCOLOGY, 2024, 31 (08) : 4728 - 4745
  • [23] Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer
    Tomohiro Ochi
    Hiroko Tsunoda
    Naoko Matsuda
    Fumi Nozaki
    Koyu Suzuki
    Hiroyuki Takei
    Hideko Yamauchi
    Breast Cancer, 2021, 28 : 838 - 847
  • [24] Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations
    Katherine Clifton
    Angelica Gutierrez-Barrera
    Junsheng Ma
    Roland Bassett
    Jennifer Litton
    Henry Kuerer
    Stacy Moulder
    Constance Albarracin
    Gabriel Hortobagyi
    Banu Arun
    Breast Cancer Research and Treatment, 2018, 170 : 101 - 109
  • [25] Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations
    Clifton, Katherine
    Gutierrez-Barrera, Angelica
    Ma, Junsheng
    Bassett, Roland, Jr.
    Litton, Jennifer
    Kuerer, Henry
    Moulder, Stacy
    Albarracin, Constance
    Hortobagyi, Gabriel
    Arun, Banu
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (01) : 101 - 109
  • [26] Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients
    Johnson, Jeffrey E.
    Strassle, Paula D.
    de Oliveira, Guilherme C.
    Agala, Chris B.
    Spanheimer, Philip
    Gallagher, Kristalyn
    Ollila, David
    Muss, Hyman
    Downs-Canner, Stephanie
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) : 509 - 520
  • [27] Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients
    Jeffrey E. Johnson
    Paula D. Strassle
    Guilherme C. de Oliveira
    Chris B. Agala
    Philip Spanheimer
    Kristalyn Gallagher
    David Ollila
    Hyman Muss
    Stephanie Downs-Canner
    Breast Cancer Research and Treatment, 2021, 189 : 509 - 520
  • [28] Neoadjuvant treatment for HER2-positive breast cancer
    Takada, Masahiro
    Toi, Masakazu
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [29] SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
    Bartsch, Rupert
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2021, 14 (03) : 247 - 251
  • [30] Survival of triple-negative and HER2-positive breast cancer by AJCC stage.
    Caggiano, V.
    Bauer, K.
    Parise, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345